Step Therapy Requirements

Effective 01/01/2027

ARB Step

Products Affected

- *azilsartan medoxomil 40 mg tablet*
- *azilsartan medoxomil 80 mg tablet*
- EDARBI 40 MG TABLET
- EDARBI 80 MG TABLET
- EDARBYCLOR 40 MG-12.5 MG TABLET
- EDARBYCLOR 40 MG-25 MG TABLET

Details

Criteria	PENDING CMS REVIEW

Bempedoic Acid Step

Products Affected

- NEXLETOL 180 MG TABLET
- NEXLIZET 180 MG-10 MG TABLET

Details

Criteria	PENDING CMS REVIEW

Fluticasone HFA step

Products Affected

- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*

Details

Criteria	Coverage of fluticasone HFA requires a trial of Qvar inhaler. If the drug is being requested for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome (cGvHD-BOS) after allogeneic hematopoietic stem cell transplantation (alloHSCT), then the prerequisite trial is not required. If the required drug appears in the prescription profile in the last 365 days, then additional documentation is not required.

Penicillamine Step

Products Affected

- *penicillamine 250 mg capsule*
- *trientine 250 mg capsule*
- *trientine 500 mg capsule*

Details

Criteria	Coverage of penicillamine capsules or trientine capsules requires a trial of penicillamine tablets (generic for Depen). If the required drug appears in the prescription profile in the last 365 days, then additional documentation is not required.

INDEX OF DRUGS

azilsartan medoxomil 40 mg tablet 1
azilsartan medoxomil 80 mg tablet 1
EDARBI 40 MG TABLET 1
EDARBI 80 MG TABLET 1
EDARBYCLOR 40 MG-12.5 MG TABLET 1
EDARBYCLOR 40 MG-25 MG TABLET 1
fluticasone propionate 110 mcg/actuation hfa aerosol inhaler 3
fluticasone propionate 220 mcg/actuation hfa aerosol inhaler 3
fluticasone propionate 44 mcg/actuation hfa aerosol inhaler 3
NEXLETOL 180 MG TABLET 2
NEXLIZET 180 MG-10 MG TABLET 2
penicillamine 250 mg capsule 4
trientine 250 mg capsule 4
trientine 500 mg capsule 4